바로가기메뉴

본문 바로가기 주메뉴 바로가기
 

logo

  • KOREAN
  • P-ISSN3022-6805
  • E-ISSN3022-6791
  • KCI

A Case Report on the Improvement of Pancreatic Cancer Complications Using Ortho-Cellular Nutrition Therapy (OCNT)

CELLMED / CELLMED, (P)3022-6805; (E)3022-6791
2025, v.15 no.12, pp.4-6
https://doi.org/10.5667/CellMed.spc.141
Jeonga Park (Inje Pharmacy)

Abstract

Objective: Pancreatic cancer is one of the leading causes of cancer-related mortality and remains among the most lethal malignant neoplasms worldwide. According to the Global Cancer Observatory estimates in 2012, pancreatic cancer accounts for more than 331,000 deaths annually, representing approximately 4% of all cancer-related deaths. Survival rates in patients with pancreatic cancer are influenced by multiple factors, including tumor type and stage at diagnosis. Currently, no recommended screening method exists for the prevention of pancreatic cancer; therefore, primary prevention is of paramount importance. Case Report: The patient in this case was a Korean male in his 60s, diagnosed with pancreatic cancer in August 2022. He underwent partial pancreatectomy combined with splenectomy and cholecystectomy, followed by a total of 18 cycles of chemotherapy over six months. As a complication, the patient developed diabetes mellitus with an elevated hemoglobin A1c level. Consequently, Ortho-Cellular Nutrition Therapy (OCNT), comprising anthocyanins, Momordica charantia (bitter melon) extract, curcumin, and post-symbiotics, was administered. The patient has continued OCNT since November 2022, and as of September 2025, hospital examinations confirmed recovery to normal ranges. Conclusion: This report is limited by its single-patient design and thus cannot be generalized to all patients with pancreatic cancer–related diabetes. Nevertheless, sustained OCNT was associated with improvements in blood glucose levels and body weight, which may represent clinically meaningful outcomes. With the patient’s consent, we present this case.

keywords
Ortho-Cellular Nutrition Therapy (OCNT), pancreatic cancer, chemotherapy, diabetes mellitus, anthocyanins, Momordica charantia extract
Received
2025-09-26
Revised
2025-09-29
Accepted
2025-09-30
Published
2025-09-30

CELLMED